Tuesday, May 30, 2023

561.316.3330

Biotechnology News Magazine

ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Biren Amin, M.B.A., to its board of directors.

Biren Amin has been the chief financial officer (CFO) and chief strategy officer of Pyramid Biosciences, Inc. since August 2022. He also serves as a co-director on the board of trustees of Axiom REACH Foundation, a non-profit organization focused on addressing public health disparities.

Sheila Gujrathi, M.D., chair of ImmPACT Bio’s board of directors said:

“It is my pleasure to welcome Biren to the board of ImmPACT Bio. Biren Amin is a seasoned executive who is highly experienced in capital markets, finance, and corporate strategy. Biren’s broad and deep expertise will be invaluable as we continue to build the company to advance our pipeline of next-generation CAR T-cell therapies.”

“This year we are rapidly advancing our novel bispecific CAR to treat aggressive B-cell lymphoma into Phase 1/2 clinical trials,” said Sumant Ramachandra, M.D., Ph.D., president and chief executive officer of ImmPACT Bio. “Biren’s world-class experience in the cell therapy space as a biotechnology equity analyst at a top investment bank, along with his knowledge of finance and capital markets, will help us implement robust strategies to grow the company and move our next-generation CAR T-cell therapies through the clinic and ultimately to patients.”

“ImmPACT Bio’s portfolio of logic-gate-based CAR T-cell therapies holds tremendous potential to transform how we treat cancers,” said Mr. Amin. “I am excited to work with this dynamic board and talented leadership team to help ImmPACT Bio achieve its vision of developing transformative oncology medicines for cancer patients who are in desperate need of new treatment options.”

Previously, Mr. Amin was CFO of Immuneering Corporation and led its IPO in mid-2021. Before his pivot to industry, Mr. Amin spent nearly two decades on Wall Street building a strong track record covering small and mid-cap biotechnology companies. He was managing director and senior biotechnology analyst at Jefferies Financial Group and earned industry recognition from Financial Times/StarMine and Institutional Investor. Earlier in his career, Mr. Amin held positions within business development and medical affairs functions at Aventis Pharmaceuticals. He holds an M.B.A. from the Stern School of Business at New York University and earned his M.S. in pharmacy from Long Island University, and a B.S. in pharmacy from the University of Sciences in Philadelphia.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine